Literature DB >> 26908559

Significance of Tumor Stage in Sinonasal Undifferentiated Carcinoma Survival: A Population-Based Analysis.

Edward C Kuan1, Armin Arshi2, Jon Mallen-St Clair2, Bobby A Tajudeen3, Elliot Abemayor2, Maie A St John4.   

Abstract

OBJECTIVE: To describe the incidence and determinants of survival of patients with sinonasal undifferentiated carcinoma (SNUC) from 1973 to 2011 using the SEER database (Surveillance, Epidemiology, and End Results), with consideration of tumor stage based on the Kadish system. STUDY
DESIGN: Retrospective database analysis.
SETTING: Academic medical center. SUBJECTS AND METHODS: The SEER registry was utilized to calculate survival trends for 328 patients with SNUC between 1973 and 2011. Patient data were then analyzed with respect to histopathology, age, sex, race, subsite, modified Kadish stage, tumor size, and treatments rendered.
RESULTS: The cohort was composed of 61.9% males with median age of 60 years. The median overall survival (OS) was 1.9 years. Most tumors presented in the nasal cavity, maxillary sinus, and ethmoid sinus (29.3%, 27.4%, 21%, respectively); 43.7% of patients received both surgical and radiation therapy. OS at 2, 5, and 10 years was 43%, 30%, and 25%, respectively. On univariate analysis, age, Kadish stage, and tumor size were associated with worse OS and disease-specific survival (DSS), while surgery and radiation therapy were associated with improved OS and DSS (all P < .05). On multivariate analysis, radiation therapy and lower Kadish stage were associated with improved OS and DSS, while younger age was additionally associated with improved OS (all P < .05).
CONCLUSION: SNUC is a rare but aggressive sinonasal malignancy. Tumor stage as determined by the Kadish system is associated with worse survival, with radiation therapy appearing to play a key role in therapeutic management. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2016.

Entities:  

Keywords:  epidemiology; outcomes; sinonasal undifferentiated carcinoma

Mesh:

Year:  2016        PMID: 26908559     DOI: 10.1177/0194599816629649

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  Sinonasal Undifferentiated Carcinoma: A 15-Year Single Institution Experience.

Authors:  Alan D Workman; Robert M Brody; Edward C Kuan; Esther Baranov; Steven G Brooks; Michelle Alonso-Basanta; Jason G Newman; Christopher H Rassekh; Ara A Chalian; Alexander G Chiu; Gregory S Weinstein; Michael D Feldman; Nithin D Adappa; Bert W O'Malley; James N Palmer
Journal:  J Neurol Surg B Skull Base       Date:  2018-08-16

2.  Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma.

Authors:  Moran Amit; Ahmed S Abdelmeguid; Teemaranawich Watcherporn; Hideaki Takahashi; Samantha Tam; Diana Bell; Renata Ferrarotto; Bonnie Glisson; Michael E Kupferman; Dianna B Roberts; Shirley Y Su; Shaan M Raza; Franco DeMonte; Ehab Y Hanna
Journal:  J Clin Oncol       Date:  2019-01-07       Impact factor: 44.544

Review 3.  Rare Diseases of the Nose, the Paranasal Sinuses, and the Anterior Skull Base.

Authors:  Fabian Sommer
Journal:  Laryngorhinootologie       Date:  2021-04-30       Impact factor: 1.057

Review 4.  Elective neck treatment in sinonasal undifferentiated carcinoma: Systematic review and meta-analysis.

Authors:  Muhammad Faisal; Rudolf Seemann; Claudia Lill; Sasan Hamzavi; Arno Wutzl; Boban M Erovic; Stefan Janik
Journal:  Head Neck       Date:  2020-01-10       Impact factor: 3.147

5.  Factors Contributing to Diagnosis and Prognosis in Sinonasal Malignancies.

Authors:  Wenjing Li; Jianqiang You; Haixiang Xue; Changjiang Chao
Journal:  J Immunol Res       Date:  2022-09-29       Impact factor: 4.493

6.  Long-term follow-up of a patient with malignant transformation of inverted papilloma into sinonasal undifferentiated carcinoma.

Authors:  Carolyn A Orgain; Terry Y Shibuya; Lester D Thompson; David B Keschner; Rohit Garg; Jivianne T Lee
Journal:  Allergy Rhinol (Providence)       Date:  2017-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.